Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH

Vaccine

Volumn 23, Issue 35, 2005, Pages 4427-4435

  Zeng, Weiguang ^a   Gauci, Sonja ^a   Ghosh, Souravi ^a   Walker, John ^b   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSL LIMITED   (Australia)

Author keywords

Immunocontraceptive vaccine; LHRH; Lipopeptide vaccine; Luteinising hormone releasing hormone

Indexed keywords

4 AMINOBUTYRIC ACID; ALANINE; AMINO ACID; ANTIBODY; ANTIGEN; CARBOCISTEINE; CD4 ANTIGEN; CONTRACEPTIVE VACCINE; CYSTEINE; DIMER; EPITOPE; GONADORELIN; IMMUNOLOGICAL ADJUVANT; ISCOMATRIX; LIPOPEPTIDE; LYSYLLEUCYLISOLEUCYLPROLYLASPARAGINYLALANYLSERYLLEUCYLISOLEUCYLGLUTAMYL ASPARAGINE CARBOXYMETHYLCYSTEINYLTHREONYLLYSYLALANYLGLUTAMYLLEUCYLHISTIDYLTRYPTOPHANYL SERYLTYROSYLGLYCYLLEUCYLARGINYLPROLYLGLYCINE LUTEINIZING HORMONE RELEASING HORMONE; LYSYLLEUCYLISOLEUCYLPROLYLASPARAGINYLALANYLSERYLLEUCYLISOLEUCYLGLUTAMYL ASPARAGINYL AMINOBUTYRIC ACID THREONYLLYSYLALANYLGLUTAMYLLEUCYLHISTIDYLTRYPTOPHYLSERYLTYROSYLGLYCYLLEUCYL ARGINYLPROLYLGLYCINE LUTEINIZING HORMONE RELEASING HORMONE; LYSYLLEUCYLISOLEUCYLPROLYLASPARAGINYLALANYLSERYLLEUCYLISOLEUCYLGLUTAMYL ASPARAGINYLALANYLTHREONYLLYSYLALANYLGLUTAMYLLEUCYLHISTIDYLTRYPTOPHYLSERYL TYROSYLGLYCYLLEUCYLARGINYLPROLYLGLYCINE LUTEINIZING HORMONE RELEASING HORMONE; LYSYLLEUCYLISOLEUCYLPROLYLASPARAGINYLALANYLSERYLLEUCYLISOLEUCYLGLUTAMYL ASPARAGINYLCYSTEINYLTHREONYLLYSYLALANYLGLUTAMYLLEUCYLHISTIDYLTRYPTOPHYLSERYL TYROSYLGLYCINYLLEUCYLARGINYLPROLYLGLYCINE LUTEINIZING HORMONE RELEASING HORMONE; LYSYLLEUCYLISOLEUCYLPROLYLASPARAGINYLALANYLSERYLLEUCYLISOLEUCYLGLUTAMYL ASPARAGINYLSERYLTHREONYLLYSYLALANYLGLUTAMYLLEUCYLHISTIDYLTRYPTOPHYLSERYLTYROSYL GLYCYLLEUCYLPROLYLARGINYLGLYCINE LUTEINIZING HORMONE RELEASING HORMONE; PEPTIDE; SERINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; BONE MARROW CELL; CELL COUNT; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; HELPER CELL; IMMUNE RESPONSE; IMMUNOCONTRACEPTION; IMMUNOGENICITY; INOCULATION; LOW DRUG DOSE; MEASUREMENT; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; SECRETORY CELL; SPLEEN CELL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGENS; CONTRACEPTION, IMMUNOLOGIC; EPITOPES; GONADOTROPIN-RELEASING HORMONE; MICE; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, CONTRACEPTIVE;

EID: 22244434478     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.04.015     Document Type: Article

References (29)

1. D.C. Jackson, A.W. Purcell, C.J. Fitzmaurice, W. Zeng, and D.N. Hart The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer Curr Drug Targets 3 2002 175 196
2. D.C. Jackson, C.J. Fitzmaurice, L.E. Brown, and W. Zeng Preparation and properties of totally synthetic immunogens Vaccine 18 1999 355 361
3. L. BenMohamed, S.L. Wechsler, and A.B. Nesburn Lipopeptide vaccines - yesterday, today, and tomorrow Lancet Infect Dis 2 2002 425 431
4. J.M. Calvo-Calle, J. Hammer, F. Sinigaglia, P. Clavijo, Z.R. Moya-Castro, and E.H. Nardin Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein J Immunol 159 1997 1362 1373
5. J. Hammer, P. Valsasnini, and K. Tolba Promiscuous and allele-specific anchors in HLA-DR-binding peptides Cell 74 1993 197 203
6. K. Deres, H. Schild, K.H. Wiesmuller, G. Jung, and H.G. Rammensee In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine Nature 342 1989 561 564
7. K.H. Wiesmuller, W.G. Bessler, and G. Jung Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response Int J Pept Protein Res 40 1992 255 260
8. W. Zeng, D.C. Jackson, and K. Rose Synthesis of a new template with a built-in adjuvant and its use in constructing peptide vaccine candidates through polyoxime chemistry J Pept Sci 2 1996 66 72
9. W. Zeng, D.C. Jackson, J. Murray, K. Rose, and L.E. Brown Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens Vaccine 18 2000 1031 1039
10. W. Zeng, S. Ghosh, Y.F. Lau, L.E. Brown, and D.C. Jackson Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines J Immunol 169 2002 4905 4912
11. L. McLain, Z. Durrani, L.A. Wisniewski, C. Porta, G.P. Lomonossoff, and N.J. Dimmock Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus Vaccine 14 1996 799 810
12. T.R. Doel Optimisation of the immune response to foot-and-mouth disease vaccines Vaccine 17 1999 1767 1771
13. S.J. Cox, N. Aggarwal, R.J. Statham, and P.V. Barnett Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines Vaccine 21 2003 1336 1347
14. S. Ghosh, and D.C. Jackson Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines Int Immunol 11 1999 1103 1110
15. S. Ghosh, J. Walker, and D.C. Jackson Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus Immunology 104 2001 58 66
16. R.A. Macdonald, C.S. Hosking, and C.L. Jones The measurement of relative antibody affinity by ELISA using thiocyanate elution J Immunol Methods 106 1988 191 194
17. M.K. Slifka, and R. Ahmed Long-lived plasma cells: a mechanism for maintaining persistent antibody production Curr Opin Immunol 10 1998 252 258
18. M.K. Slifka, and R. Ahmed B cell responses and immune memory Dev Biol Stand 95 1998 105 115
19. R.A. Manz, A. Thiel, and A. Radbruch Lifetime of plasma cells in the bone marrow Nature 388 1997 133 134
20. R. Benner, W. Hijmans, and J.J. Haaijman The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation Clin Exp Immunol 46 1981 1 8
21. M.M. Rweyemamu, L. Black, A. Boge, A.C. Thorne, and G.M. Terry The relationship between the 140S antigen dose in aqueous foot-and-mouth disease vaccines and the serum antibody response of cattle J Biol Stand 12 1984 111 120
22. ® Vaccine 20 2001 490 497
23. R.G. Windon, P.J. Chaplin, and L. Beezum Induction of lymphocyte recruitment in the absence of a detectable immune response Vaccine 19 2000 572 578
24. ® adjuvanted influenza vaccine Vaccine 21 2003 946 949
25. W. Chen, J.W. Yewdell, R.L. Levine, and J.R. Bennink Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants J Exp Med 189 1999 1757 1764
26. M. Baratin, M. Kayibanda, and M. Ziol Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self-tumour epitope J Pept Sci 8 2002 327 334
27. P.E. Jensen Reduction of disulfide bonds during antigen processing: evidence from a thiol-dependent insulin determinant J Exp Med 174 1991 1121 1130
28. P.E. Jensen Antigen unfolding and disulfide reduction in antigen presenting cells Semin Immunol 7 1995 347 353
29. B.F. Hoyer, K. Moser, and A.E. Hauser Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice J Exp Med 199 2004 1557 1584